The role of IL‐23 and the IL‐23/TH17 immune axis in the pathogenesis and treatment of psoriasis
G Girolomoni, R Strohal, L Puig… - Journal of the …, 2017 - Wiley Online Library
Psoriasis is a chronic, immune‐mediated disease affecting more than 100 million people
worldwide and up to 2.2% of the UK population. The aetiology of psoriasis is thought to …
worldwide and up to 2.2% of the UK population. The aetiology of psoriasis is thought to …
Current knowledge on psoriasis and autoimmune diseases
N Ayala-Fontánez, DC Soler… - Psoriasis: Targets and …, 2016 - Taylor & Francis
Psoriasis is a prevalent, chronic inflammatory disease of the skin, mediated by crosstalk
between epidermal keratinocytes, dermal vascular cells, and immunocytes such as antigen …
between epidermal keratinocytes, dermal vascular cells, and immunocytes such as antigen …
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris–Part 1: treatment and monitoring recommendations
A Nast, C Smith, PI Spuls, G Avila Valle… - Journal of the …, 2020 - Wiley Online Library
This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …
developed following the EuroGuiDerm Guideline and Consensus Statement Development …
Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity …
CA Elmets, NJ Korman, EF Prater, EB Wong… - Journal of the American …, 2021 - Elsevier
Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the
United States population. This guideline addresses important clinical questions that arise in …
United States population. This guideline addresses important clinical questions that arise in …
Hyaluronic acid-based dissolving microneedle patch loaded with methotrexate for improved treatment of psoriasis
H Du, P Liu, J Zhu, J Lan, Y Li, L Zhang… - … applied materials & …, 2019 - ACS Publications
Methotrexate (MTX) is one of the first-line treatments for moderate to severe psoriasis, while
the side effects caused by injection and oral administration of MTX greatly restrict its clinical …
the side effects caused by injection and oral administration of MTX greatly restrict its clinical …
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
CEM Griffiths, K Reich, M Lebwohl, P Van De Kerkhof… - The Lancet, 2015 - thelancet.com
Background Ixekizumab is a humanised monoclonal antibody against the proinflammatory
cytokine interleukin 17A. We report two studies of ixekizumab compared with placebo or …
cytokine interleukin 17A. We report two studies of ixekizumab compared with placebo or …
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized …
C Paul, J Cather, M Gooderham… - British Journal of …, 2015 - academic.oup.com
Background Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …
European evidence‐based (S3) guideline for the treatment of acne–update 2016–short version
A Nast, B Dréno, V Bettoli… - Journal of the …, 2016 - Wiley Online Library
European evidence‐based (S3) guideline for the treatment of acne – update 2016 – short
version - Nast - 2016 - Journal of the European Academy of Dermatology and Venereology …
version - Nast - 2016 - Journal of the European Academy of Dermatology and Venereology …
Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP
Generalized pustular psoriasis (GPP) is a rare disease characterized by recurrent fever and
systemic flushing accompanied by extensive sterile pustules. The committee of the …
systemic flushing accompanied by extensive sterile pustules. The committee of the …
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
H Bachelez, PCM Van De Kerkhof, R Strohal… - The Lancet, 2015 - thelancet.com
Background New therapeutic options are needed for patients with psoriasis. Tofacitinib, an
oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe …
oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe …